title: In search of mechanisms associated with mesenchymal stem cell-based therapies for acute kidney injury.
abstract: Acute kidney injury (AKI) is classically described as a rapid loss of kidney function. AKI affects more than 15% of all hospital admissions and is associated with elevated mortality rates. Although many advances have occurred, intermittent or continuous renal replacement therapies are still considered the best options for reversing mild and severe AKI syndrome. For this reason, it is essential that innovative and effective therapies, without side effects and complications, be developed to treat AKI and the end-stages of renal disease. Mesenchymal stem cell (MSC) based therapies have numerous advantages in helping to repair inflamed and damaged tissues and are being considered as a new alternative for treating kidney injuries. Numerous experimental models have shown that MSCs can act via differentiation-independent mechanisms to help renal recovery. Essentially, MSCs can secrete a pool of cytokines, growth factors and chemokines, express enzymes, interact via cell-to-cell contacts and release bioagents such as microvesicles to orchestrate renal protection. In this review, we propose seven distinct properties of MSCs which explain how renoprotection may be conferred: 1) anti-inflammatory; 2) pro-angiogenic; 3) stimulation of endogenous progenitor cells; 4) anti-apoptotic; 5) anti-fibrotic; 6) anti-oxidant; and 7) promotion of cellular reprogramming. In this context, these mechanisms, either individually or synergically, could induce renal protection and functional recovery. This review summarises the most important effects and benefits associated with MSC-based therapies in experimental renal disease models and attempts to clarify the mechanisms behind the MSC-related renoprotection. MSCs may prove to be an effective, innovative and affordable treatment for moderate and severe AKI. However, more studies need to be performed to provide a more comprehensive global understanding of MSC-related therapies and to ensure their safety for future clinical applications.
authors.affiliation: Department of Medicine, Division of Nephrology, Universidade Federal de São Paulo, Brazil; ; Laboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Science IV, Universidade de São Paulo, Brazil.
authors.forename: Danilo C
authors.initials: DC
authors.lastname: de Almeida
authors.affiliation: Department of Medicine, Division of Nephrology, Universidade Federal de São Paulo, Brazil;
authors.forename: Cassiano
authors.initials: C
authors.lastname: Donizetti-Oliveira
authors.affiliation: Department of Medicine, Division of Nephrology, Universidade Federal de São Paulo, Brazil;
authors.forename: Priscilla
authors.initials: P
authors.lastname: Barbosa-Costa
authors.affiliation: Department of Medicine, Division of Nephrology, Universidade Federal de São Paulo, Brazil;
authors.forename: Clarice St
authors.initials: CS
authors.lastname: Origassa
authors.affiliation: Department of Medicine, Division of Nephrology, Universidade Federal de São Paulo, Brazil; ; Laboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Science IV, Universidade de São Paulo, Brazil.
authors.forename: Niels Os
authors.initials: NO
authors.lastname: Câmara